Aimeike (300896) Annual Report Review Report: Diversified Pipelines Drive Steady Growth and Gradually Strengthen Platformization Capabilities
Ameke (300896): Rapid growth in performance, outstanding performance of gel products
Aimeike (300896): Solution injection products are growing steadily, and “Wet White Angel” continues its good growth trend
Aimeike (300896): Core product growth continues to build future growth poles
Aimeike (300896): Excellent annual performance growth, channel penetration and brand influence continued to increase
Aimeike (300896) 2023 Annual Review: High Wetness Volume Growth, Steady Profit
Aimeike (300896): The high increase in performance is in line with expectations, and the new product pipeline is progressing steadily
Aimeike (300896): The 23-year equity incentive target was exceeded, and the wet white angel and the water light needle increased
Aimeike (300896): Performance is in line with expectations and continues to broaden the boundaries of the product matrix
Aimeike (300896): Good product growth, multi-line layout, sufficient product reserves
Aimeike (300896): 23 years of steady implementation, high growth, continuous improvement of medical and aesthetic leaders
Aimeike (300896): White Angel continues to increase its status as the king of medicine and beauty
Aimeike (300896): Net profit returned to mother increased 47%, pipeline growth continues to be verified
Aimeike (300896): Maintaining high growth in 2023, diversified product matrices continue to be enriched
Aimeike (300896): The pipeline layout is getting better and the product market penetration rate is further increasing
Aimeike (300896) Company Review Report: Channel Expansion Breaks Through 7,000 Penetrations, Hi Sports Is Expected to Welcome Higher Resilience
Aimeike (300896): Performance is in line with expectations, “Wet White Angel” achieved rapid growth
Aimeike (300896): Continued growth in performance, steady expansion of sales channels
Aimeike (300896): Net profit increased by 47% in '23 and exceeded the equity incentive target
Aimeike (300896) Review Report: Performance Continues to Grow High, Product Pipeline Improves
No Data